Moderna Inc. ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A ; Dividend Yield, N/A ; Latest Dividend, N/A. MRNA's current price target is $ Learn why top analysts are making this stock forecast for Moderna at MarketBeat. According to the latest long-term forecast, Moderna price will hit $80 by the end of and then $ by the end of Moderna will rise to $ within the. What is the Moderna stock forecast? The Moderna stock forecast for tomorrow is $ , which would represent a % loss compared to the current price. In. Find the latest Moderna, Inc. MRNA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
View Moderna, Inc MRNA investment & stock information. Get the latest Moderna future, which can give investors an advantage in earnings season. The. Moderna Inc real time quote is equal to USD at , but your current investment may be devalued in the future. Current Price: USD. 7 Days. Moderna Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - Moderna's vaccine is turning out to be hugely profitable, which recorded an incredible 70% net profit margin over Q1 Trading hours of Moderna (MRNA) with. Moderna Stock Smart Score ; Analyst Consensus. Moderate Buy. Average Price Target: $ (% Upside) ; Blogger Sentiment. Neutral. MRNA Sentiment 57% Sector. Stock Price Forecast The 11 analysts with month price forecasts for Moderna stock have an average target of , with a low estimate of 65 and a high. Moderna is a commercial-stage biotech that was founded in and had its initial public offering in December The firm's mRNA technology was rapidly. TD Cowen analyst Tyler Van Buren lowered the price target on Moderna (NASDAQ: MRNA) to $ (from $) while maintaining a Hold rating. The analyst. Moderna's stock value rising is contingent upon its ability to Which stocks are best for without any risk and have future growth? Find the latest Moderna Inc (MRNA) stock forecast, month price target, predictions and analyst recommendations. Moderna, Inc. reached a 4-year low as its fiscal year revenue outlook did not meet consensus expectations. Barclays maintained an Overweight rating for.
Real time Moderna (MRNA) stock price quote, stock graph, news & analysis These players have had their ups and downs -- but the future looks bright. Moderna's Financial Forecast Dims: Sell Recommendation Amidst R&D and Regulatory Hurdles MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts. We assume demand for COVID vaccines will remain at trough levels for the foreseeable future. Karen Andersen, CFA Oct 16, Share. MRNA stock results show that Moderna beat analyst estimates for earnings per share and beat on revenue for the first quarter of What are your thoughts on Moderna Stock forecast? Company Discussion. In a cross post under r/tech Moderna is working on Melanoma Cancer trials. future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as. View Moderna, Inc. MRNA stock quote prices, financial information, real-time forecasts, and company news from CNN. - MRNA Stock was down % · The bearish movement in Moderna's stock today could be attributed to profit-taking by investors after a period of. According to 12 Wall Street analysts that have issued a 1 year MRNA price target, the average MRNA price target is $, with the highest MRNA stock price.
MRK stock. Is Moderna stock a stock to buy now? In the video below Future AI Winners: Nvidia & Snowflake Stock Guide. Mr. FIRED Up. Moderna Inc MRNA:NASDAQ ; Open ; Day High ; Day Low ; Prev Close ; 52 Week High The forecasts range from a low of $ to a high of $ A stock's price target is the price at which analysts consider it fairly valued with respect to. Stock futures higher on Fed minutes relief, tech boost; Nvidia shares surge as AI chip demand powers solid sales outlook; Moderna earnings on deck as. Moderna is forecast to grow earnings and revenue by % and % per annum respectively. EPS is expected to grow by 61% per annum. Return on equity is.